Johns Hopkins Medicine researchers have revamped an anti-cancer drug to better target cancer cells and leave healthy tissues unharmed. Scientists have dubbed this type of targeted approach a "prodrug"—a medicine designed ...
Nov 16, 2022
0
1583
A new form of cancer immunotherapy has been given to a University of California, San Diego Health patient in the first test of immune cells grown from stem cells.
Apr 16, 2019
0
103
Adoptively transferred T-cells can prolong survival and sometimes cure patients with advanced solid tumors. While promising, it can take months to generate the necessary T-cells to help these patients. Such slow speed makes ...
Oct 30, 2020
0
22
In a first-in-human, Phase I trial, researchers at The University of Texas MD Anderson Cancer Center discovered that ATR inhibitor RP-3500 was safe and well tolerated with promising clinical benefit. Principal investigator ...
Oct 8, 2021
0
29
Over the last decade, immune checkpoint blockers, or ICBs, have revolutionized treatment for various advanced cancers, including melanoma, the most aggressive skin cancer that was considered largely incurable not long ago. ...
Sep 19, 2022
0
67
A novel therapy designed to help stimulate the body's immune system response against cancer appears to be safe to use as alone or in combination with immune checkpoint inhibitors, according to an early phase clinical trial ...
Nov 30, 2020
0
3
A new study validating the clinical utility of a proprietary pan-solid tumor predictive biomarker for anti-PD-1/PD-L1 checkpoint inhibitor monotherapy benefit—called Immunotherapy Response Score (IRS)—was published in ...
Feb 7, 2023
0
1
Cancer patients who are ineligible for clinical trials receive immune checkpoint inhibitors (ICI) at greater rates than patients who are trial eligible despite no survival benefit, according to a new study by researchers ...
Nov 9, 2021
0
67
A novel three-drug combination achieved notable responses in patients with advanced HER2-negative breast cancer, according to new research directed by investigators from the Johns Hopkins Kimmel Cancer Center.
Feb 14, 2024
0
19
A new analysis finds that nearly three-quarters of 500 patients with advanced cancer could be referred to a potential targeted treatment based on the results of a comprehensive analysis of their tumor's genetic landscape.
Jun 2, 2017
0
2
